Current cardiovascular disease prevention strategies are based on the management of
cardiovascular risk as a continuum, redefining the therapeutic goals for each individual …

The prevalence of multicomponent therapy in treatment of cardiovascular diseases makes
fixed combinations of drugs very useful. The fixed combination of rosuvastatin with ACE …

BACKGROUND: In order to prevent cardiovascular events, it is essential to effectively
manage overall risk of cardiovascular disease. However, despite guideline …

In order to prevent cardiovascular events, it is essential to effectively manage overall risk of
cardiovascular disease. However, despite guideline recommendations to this effect, current …

Clinical guidelines now recognize the importance of a multifactorial approach to managing
cardiovascular (CV) risk. This idea was taken a step further with the concept of the Polypill™ …

In 2002, the World Health Organization estimated that over 58% of cardiovascular disease in
North America is due to 'both blood pressure and cholesterol higher than optimal' …

Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …

The authors performed this study to investigate the efficacy and safety of a rosuvastatin
(RSV)/amlodipine (AML) polypill compared with those of atorvastatin (ATV)/AML polypill. We …

Abundant evidence from large-scale clinical trials supports the importance of lowering low-
density lipoprotein cholesterol (LDL-C) to decrease the risk of cardiovascular disease (CVD) …

In Russia, target blood pressure (BP) levels are achieved in only 14.4% of men and in
30.9% of women. The need for combination therapy of hypertension is as high as 70.7 …